Puma Biotechnology logo
Puma Biotechnology
PBYI | NASDAQ
Chart Builder DCF Calculator
$7.34
-$0.43 (-5.53%)
At close: Nov 16, 2026, 4:00 PM ET
$7.20
-$0.14 (-1.91%)
After-hours: Nov 16, 2026, 7:30 PM ET

Puma Biotechnology Company Profile

Company profile explained

Company Profile

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.

Key Executives

Name Position
Alan H. Auerbach Founder, Chairman, President, Chief Executive Officer & Secretary
Maximo F. Nougues Chief Financial Officer & Principal Accounting Officer
Douglas Hunt FRAPS Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer
Gordon G. Esplin Chief Accounting Officer
Heather Blaber Senior Vice President of Marketing
Kenneth Wiehe Senior Vice President of Supply Chain & Manufacturing
Mariann Ohanesian Senior Director of Investor Relations
Pamela Wilson Senior Vice President of Clinical Operations
Petra Rietschel Senior Vice President of Clinical Development
Roger L. Storms Senior Vice President of Sales

Latest SEC Filings

Date Type Title
Oct 06, 2026 SC 13D/A [Amend] Filing
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 08, 2026 4 Filing
Jul 08, 2026 4 Filing
Jul 08, 2026 4 Filing
Jun 16, 2026 8-K Current Report
Jun 15, 2026 4 Filing
View All SEC Filings ➞
Puma Biotechnology
Puma Biotechnology logo
Country United States
IPO Date Apr 24, 2012
Industry Biotechnology
Sector Healthcare
Employees 179
CEO Alan H. Auerbach

Contact Details

10880 Wilshire Boulevard Los Angeles, California 90024 United States

Stock Details

Ticker Symbol PBYI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001401667
CUSIP Number 74587V107
ISIN Number US74587V1070
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.